Select a medication above to begin.
acidophilus lactobacillus
Lactobacillus acidophilus
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- acne [Insufficient Evidence]
- allergic rhinitis [Insufficient Evidence]
- aphthous ulcer (canker sores) [Insufficient Evidence]
- ARDS [Insufficient Evidence]
- asthma [Insufficient Evidence]
- atopic dermatitis (eczema) [Insufficient Evidence]
- atopic dz [Possibly Ineffective]
- bacterial vaginosis [Possibly Effective]
- bronchopulmonary dysplasia [Insufficient Evidence]
- cancer [Insufficient Evidence]
- candidiasis, vulvovaginal [Insufficient Evidence]
- cholestasis [Insufficient Evidence]
- C. difficile infection prevention [Insufficient Evidence]
- colic [Insufficient Evidence]
- common cold [Insufficient Evidence]
- constipation [Insufficient Evidence]
- critical illness (trauma) [Insufficient Evidence]
- denture stomatitis [Insufficient Evidence]
- depression [Insufficient Evidence]
- diabetes [Insufficient Evidence]
- diabetic nephropathy [Insufficient Evidence]
- diarrhea [Insufficient Evidence]
- diarrhea, antibiotic-assoc. [Possibly Effective]
- diarrhea, radiation-related [Insufficient Evidence]
- diarrhea, rotaviral [Insufficient Evidence]
- generalized anxiety disorder [Insufficient Evidence]
- hepatic encephalopathy [Insufficient Evidence]
- HIV/AIDS [Insufficient Evidence]
- HTN [Insufficient Evidence]
- hypercholesterolemia [Insufficient Evidence]
- H. pylori infection [Possibly Effective]
- IBS [Possibly Effective]
- inflammatory bowel dz [Insufficient Evidence]
- intraventricular hemorrhage [Insufficient Evidence]
- lactose intolerance [Insufficient Evidence]
- Lyme dz [Insufficient Evidence]
- metabolic syndrome [Insufficient Evidence]
- nausea/vomiting, pregnancy-induced [Insufficient Evidence]
- necrotizing enterocolitis [Insufficient Evidence]
- nonalcoholic fatty liver dz [Insufficient Evidence]
- nonalcoholic steatohepatitis [Insufficient Evidence]
- obesity [Insufficient Evidence]
- polycystic ovary syndrome [Insufficient Evidence]
- postop infection [Insufficient Evidence]
- pouchitis, chronic [Insufficient Evidence]
- prematurity [Insufficient Evidence]
- psoriasis [Insufficient Evidence]
- respiratory infections [Insufficient Evidence]
- retinopathy of prematurity [Insufficient Evidence]
- rheumatoid arthritis [Insufficient Evidence]
- sepsis [Insufficient Evidence]
- short bowel syndrome [Insufficient Evidence]
- small intestinal bacterial overgrowth (SIBO) [Insufficient Evidence]
- traveler's diarrhea prophylaxis [Insufficient Evidence]
- ulcerative colitis [Insufficient Evidence]
- UTI prevention [Insufficient Evidence]
- ventilator-assoc. pneumonia prevention [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Special Note
- [formulation clarification]
- Info: uses and doses represent various probiotic-containing products; other Lactobacillus species exist, but are not included; select proprietary products noted below
- [Floranex products]
- Info: each granule packet contains 100 million CFUs Lactobacillus acidophilus and Lactobacillus bulgaricus; each tablet contains 1 million CFUs Lactobacillus acidophilus and Lactobacillus bulgaricus
- [Lactinex products]
- Info: each granule packet contains 100 million CFUs Lactobacillus acidophilus and Lactobacillus bulgaricus; each tablet contains 1 million CFUs Lactobacillus acidophilus and Lactobacillus bulgaricus
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
acne
- [Insufficient Evidence]
- Dose: 30 billion CFUs PO bid (L. acidophilus plus other probiotics); Info: used w/ minocycline
allergic rhinitis
- [Insufficient Evidence]
- Dose: 30 billion CFUs PO qd (L. acidophilus L-92)
aphthous ulcer (canker sores)
- [Insufficient Evidence]
- Dose: 3 billion CFUs lozenge PO qd (L. acidophilus plus other probiotics)
atopic dermatitis (eczema) prevention
- [Insufficient Evidence]
- Dose: 105 billion CFUs PO qd in pregnant pt starting 36 wk gestation, then cont. until 3mo postpartum (L. acidophilus La-5 plus other probiotics); Alt: 5 billion CFUs PO bid in pts 1-3 yo (L. acidophilus DDS-1 plus other probiotics); Info: for childhood prevention
bacterial vaginosis
- [Possibly Effective (PV route)]
- Dose: 100 million-1 billion CFUs PV bid x6 days (L. acidophilus); Alt: 10-20 million CFUs PV qd x6 days (L. acidophilus); 1 billion CFUs/mL douche PV qd x6 days
- [Possibly Effective (PO route)]
- Dose: 125 mL live culture yogurt PO qd (L. acidophilus); Alt: 5.4 billion CFUs PO bid x7 days, then 5.4 billion CFUs PO qd (L. acidophilus plus other probiotics)
candidiasis, vulvovaginal
- [Insufficient Evidence]
- Dose: 800 million CFUs PV qod x10 days, then 800 million CFUs PV qwk x10wk (L. acidophilus LA 02 plus other probiotics); Start: after fluconazole 200 mg PO tid x1wk
cholestasis
- [Insufficient Evidence]
- Dose: 5 million CFUs PO tid (L. acidophilus plus other probiotics); Info: for use in preterm neonates
C. difficile infection prevention
- [Insufficient Evidence]
- Dose: 50-100 billion CFUs PO qd x5 days (L. acidophilus CL1285 plus other probiotics); Info: used w/ standard tx
colic
- [Insufficient Evidence]
- Dose: 1 billion CFUs PO bid (L. acidophilus)
common cold
- [Insufficient Evidence]
- Dose: 2 billion CFUs PO bid (L. acidophilus plus other probiotics)
constipation
- [Insufficient Evidence]
- Dose: 30 billion CFUs PO bid (L. acidophilus plus other probiotics); Alt: 2 billion CFUs PO qam (L. acidophilus NCFM plus other probiotics)
critical illness (trauma)
- [Insufficient Evidence]
- Dose: 5.5 billion CFUs PO bid (L. acidophilus LA-5 plus other probiotics)
diabetes mellitus, type 1
- [Insufficient Evidence]
- Dose: 112.5 billion CFUs PO qd (L. acidophilus plus other probiotics); Info: for pts 2-12 yo
diabetes mellitus, type 2
- [Insufficient Evidence]
- Dose: 111 billion CFUs PO qd (L. acidophilus plus other probiotics); Alt: 2 billion CFUs PO qd (L. acidophilus La-5 plus other probiotics); 0.93 billion CFUs PO qd (L. acidophilus)
diabetic nephropathy
- [Insufficient Evidence]
- Dose: 3.2 billion CFUs PO qd (L. acidophilus plus other probiotics)
diarrhea, adult pts
- [Insufficient Evidence]
- Dose: 20 billion CFUs PO qd (L. acidophilus LB)
diarrhea, peds pts
- [Insufficient Evidence]
- Dose: 20-30 billion CFUs PO qd (L. acidophilus LB); Info: for pts 1 mo-4 yo; used w/ standard tx
diarrhea, antibiotic-assoc.
- [Possibly Effective]
- Dose: 20 billion CFUs PO tid (L. acidophilus); Alt: 100 billion CFUs PO qd (L. acidophilus CL1285 plus other probiotics)
diarrhea, radiation-related
- [Insufficient Evidence]
- Dose 1.75 billion CFUs PO tid (L. acidophilus LA-5 plus other probiotics); Alt: 2 billion CFUs PO bid starting 7 days before XRT (L. acidophilus plus other probiotics)
diarrhea, rotaviral
- [Insufficient Evidence]
- Dose: 22 billion CFUs PO bid (L. acidophilus AD031 plus other probiotics); Alt: 20-30 billion CFUs PO qd (L. acidophilus LB); Info: for use in peds pts
generalized anxiety disorder
- [Insufficient Evidence]
- Dose: 18 billion CFUs PO qd (L. acidophilus plus other probiotics); Info: used w/ sertraline
gestational diabetes
- [Insufficient Evidence]
- Dose: 4 billion CFUs PO qd starting 24-28 wk gestation (L. acidophilus LA-5 plus other probiotics); Alt: 112.5 billion CFUs PO bid (L. acidophilus plus other probiotics); 6 billion CFUs/g PO qd (L. acidophilus plus other probiotics)
H. pylori infection, adult pts
- [Possibly Effective]
- Dose: 5 billion CFUs PO tid x10 days (L. acidophilus LB); Alt: 10 million CFUs PO tid x6wk (L. acidophilus plus other probiotics); Info: used w/ standard tx
H. pylori infection, peds pts
- [Possibly Effective]
- Dose: 102.6 million CFUs PO qd x6wk (L. acidophilus LA-05 plus other probiotics); Info: used w/ standard tx
hypercholesterolemia
- [Insufficient Evidence]
- Dose: 39 million-2 billion CFUs PO qd (L. acidophilus); Info: used w/ or w/o other probiotics
IBS
- [Possibly Effective]
- Dose: 20 billion CFUs PO qd (L. acidophilus); Alt: 225 billion CFUs PO bid (L. acidophilus plus other probiotics); 10 billion CFUs PO qd (L. acidophilus DDS-1); 2.5 billion CFUs PO bid (L. acidophilus LA120 plus other probiotics); 10 billion CFUs PO qd (L. acidophilus NCFM plus other probiotics)
inflammatory bowel dz
- [Insufficient Evidence]
- Dose: 20 billion CFUs PO bid (L. acidophilus LA-5 plus other probiotics)
lactose intolerance
- [Insufficient Evidence]
- Dose: 400 mL non-fermented milk containing 800 million-1 billion CFUs/mL PO qd (L. acidophilus)
metabolic syndrome
- [Insufficient Evidence]
- Dose: 6 billion CFUs PO qd (L. acidophilus PBS066-DSM 24,936 plus other probiotics)
nausea/vomiting, pregnancy-induced
- [Insufficient Evidence]
- Dose: 20 billion CFUs PO qd (L. acidophilus La-14 plus other probiotics)
nonalcoholic fatty liver dz
- [Insufficient Evidence]
- Dose: 13 billion CFUs PO qd (L. acidophilus ATCC B3208 plus other probiotics); Info: for use in peds pts
obesity
- [Insufficient Evidence]
- Dose: 50 billion CFUs PO qd (L. acidophilus plus other probiotics)
polycystic ovary syndrome
- [Insufficient Evidence]
- Dose: 6 billion CFUs PO qd (L. acidophilus T16 plus other probiotics); Alt: 10 billion CFUs PO qd x2mo, then 10 billion CFUs PO bid (L. acidophilus UBLA-34 plus other probiotics)
pouchitis, chronic
- [Insufficient Evidence]
- Dose: 6 g PO qd (L. acidophilus plus other probiotics); Alt: 3.2 billion CFUs PO tid (L. acidophilus plus other probiotics)
prematurity
- [Insufficient Evidence]
- Dose: 5 million CFUs PO tid (L. acidophilus plus other probiotics); Alt: 6 billion CFUs PO qd starting 7 days after birth, then cont. until 34 wk postmenstrual age or hospital discharge (L. acidophilus NCDO 1748 plus other probiotics); 1-3 billion CFUs PO qd-bid x1mo after birth (L. acidophilus); Info: for use in preterm neonates
psoriasis
- [Insufficient Evidence]
- Dose: 2.6 billion CFUs/day PO divided bid (L. acidophilus plus other probiotics)
respiratory infections prevention, adult pts
- [Insufficient Evidence]
- Dose: 50 billion CFUs PO qd (L. acidophilus plus other probiotics)
respiratory infections prevention, peds pts
- [Insufficient Evidence]
- Dose: 10 billion CFUs PO bid (L. acidophilus NCFM plus other probiotics); Alt: 5 billion CFUs PO bid (L. acidophilus NCFM); 12.5 billion CFUs PO qd (L. acidophilus CUL21, CUL60 plus other probiotics); 5 billion CFUs PO qd (L. acidophilus DDS-1 plus other probiotics); Info: for pts 3 yo and older
sepsis, peds pts
- [Insufficient Evidence]
- Dose: 6 billion CFUs PO qd starting 7 days after birth, then cont. until 34 wk postmenstrual age or hospital discharge (L. acidophilus NCDO 1748 plus other probiotics); Alt: 1-3 billion CFUs PO qd-bid x1mo after birth (L. acidophilus)
small intestinal bacterial overgrowth (SIBO)
- [Insufficient Evidence]
- Dose: 3 g PO bid (L. acidophilus plus other probiotics)
ulcerative colitis
- [Insufficient Evidence]
- Dose: 900 billion CFUs PO qd-bid (L. acidophilus DSM24735 plus other probiotics); Info: used w/ standard tx
UTI prevention, peds pts
- [Insufficient Evidence]
- Dose: 25 mg/kg/dose PO bid (L. acidophilus plus other probiotics); Max: 1000 mg/day; Info: for pts 4 mo-5 yo
ventilator-assoc. pneumonia prevention
- [Insufficient Evidence]
- Dose: 5.5 billion CFUs PO bid (L. acidophilus LA-5 plus other probiotics)
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.